Academic partnerships

# Driving the future of AI medical research

We work with partners to apply AI to rich, multimodal data to identify new drug candidates, de-risk and accelerate clinical trials and build diagnostic solutions

## Why work with Owkin?

### Publication

Apply new technologies and latest AI methodologies.

Harness Owkin's multimodal data expertise.

70 publications in high impact journals.

### Funding & support

Owkin funds partners to accelerate their research and publication process.

We support the generation of multimodal datasets and assist in the curation and structuring of partner data.

### Compliance & privacy

World class security standards enhance patient data privacy and partner data integrity.

8+ years deploying multi-centric projects across different institutional setups.

### Data mapping

We make your datasets visible, accessible, and actionable to drive discovery, collaboration, and impact.

Identify new users, use cases, and revenue streams, all while retaining full control over how your data is used.

## Our network includes 10 of the top 20 centres globally*

We work with leading institutions to securely unlock the potential of patient data for research



*According to 2024 Newsweek rankings

Unrivalled depth of data:

## We work with our world class network to answer specific medical questions

We would like to access clinical, histological and genomic patient data with BRCA mutation in early breast cancer in order to develop a Dx tool.

| Breast cancer patients in Europe | 50% of patients have early breast cancer | Patients tested for BRCA mutation (HR+/HER2-) | Biomarker (BRCA) prevalence (5%) |
|---|---|---|---|
| **600,000** | **300,000** | **40,000** | **5,000** |



| We start with large volumes of data | Filter down to the right subpopulation | Match criteria to specific scientific questions | Work with KOLs to capture deep data on rare cohorts |
|---|---|---|---|

### Outcome

Rare target subpopulation AI-ready dataset created for research and available for centre to reuse in the future.

## We work with partners to apply AI to multimodal patient data to enable discovery and development in:

**Oncology** | **Immunology & inflammation** | **Cardiovascular disease** | **Neurology**

A selection of our scientifically robust research

**nature medicine**

Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer.

Jan 2024

**nature communications**

PacpAInt: A histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma.

Jun 2023

**nature communications**

Validation of MSIntuit CRC as an AI-based pre-screening tool for MSI detection from colorectal cancer histology slides.

Nov 2023

Scan the QR to discover our scientific publications:

Get in touch with us at owkin.com/contact



OWKIN.COM